Biotech - Spark Newswire

2 minute read

VBL Therapeutics Says Was Notified By FDA That Clearance For New VB-111 Batches Is Pending Completion Of A Technical Review; Co. Expects Shortage Of Study Drug Supply for US And Has Paused Patient Recruitment

Today, 6:12 AM

VBL Therapeutics (NASDAQ:VBLT) today provided an update on its ongoing OVAL Phase 3 study investigating ofranergene obadenovec (VB-111), for the treatment of platinum-resistant ovarian cancer. The Company was

VBLT

2 minute read

Axsome Therapeutics Announces Planned NDA Submission For AXS-14 For Management Of Fibromyalgia; Submission Anticipated In Q4

By Bill Haddad

Today, 6:12 AM

Axsome Therapeutics, Inc. (NASDAQ:AXSM), a biopharmaceutical company developing novel therapies for the management of central nervous system (CNS) disorders, today announced its plan to submit a New Drug Application

AXSM

3 minute read

Lilly Announces Head-To-Head Study Comparing Once-Monthly Emgality With Every-Other-Day Nurtec ODT For Preventive Treatment Of Migraine

By Bill Haddad

Today, 6:12 AM

To advance the science of migraine treatment and aid the understanding of calcitonin gene-related peptide (CGRP) monoclonal antibodies (mAbs) compared to oral CGRP receptor antagonists in the prevention of migraine, Eli

LLY

6 minute read

Sage Therapeutics And Biogen Announce Pivotal Phase 3 Results For Zuranolone In Major Depressive Disorder; Study Met Primary Endpoint

By Bill Haddad

Today, 6:12 AM

At the Day 15 primary endpoint, zuranolone 50 mg showed a statistically significant and clinically meaningful reduction in depressive symptoms as measured by HAMD-17 (p=0.0141) compared to placebo Rapid onset of

BIIB

2 minute read

Ampio Pharmaceuticals Receives Approval To Expand Enrollment Of AP-019 Phase II Study To India

By Bill Haddad

Today, 6:12 AM

Ampio Pharmaceuticals (NYSE:AMPE), a biopharmaceutical company focused on the advancement of immunology-based therapies for prevalent inflammatory conditions, today announced it has received regulatory approval to

AMPE

1 minute read

AstraZeneca’s Antibody Treatment Unsuccessful At Preventing Symptomatic COVID-19 Infection

By Vandana Singh

Today, 6:12 AM

AstraZeneca Plc (NASDAQ:AZN) reported data from the STORM CHASER Phase 3 trial showing that its long-acting antibody (LAAB) combination…

AZN

1 minute read

Daiichi Sankyo To Stop Testing Inhaled Nafamostat In COVID-19 Patients In Japan

By Vandana Singh

Today, 6:12 AM

Daiichi Sankyo Co Ltd (OTC:DSNKY) said it was halting the development of an existing drug for the treatment of COVID-19 without…

DSKYF

1 minute read

Yet Another Biogen’s Retinal Disease Gene Therapy Fails In Late-Stage Study

By Vandana Singh

Today, 6:12 AM

While basking in the glow of the approval for its Alzheimer’s treatment, Biogen Inc (NASDAQ:BIIB) announced that a gene therapy candidate…

BIIB

2 minute read

Biodesix Announces Commercial Availability Of SARS CoV-2 Neutralization Antibody Test

By Bill Haddad

Today, 6:12 AM

Detection of circulating neutralizing antibodies produced in response to COVID-19 vaccination and infection may benefit immunocompromised individuals. Biodesix, Inc. (NASDAQ:BDSX), a leading data-driven diagnostic

BDSX

2 minute read

NanoString And Parker Institute For Cancer Immunotherapy Collaborate To ‘Optimize Cell Therapies to Treat Cancer’; Collaboration Will Utilize nCounter Analysis System

By Bill Haddad

Today, 6:12 AM

Collaboration Will Utilize the nCounter Analysis System to Characterize CAR-T Regimens Designed to Improve Patient Outcomes NanoString Technologies, Inc. (NASDAQ:NSTG), a leading provider of life science tools for

NSTG